91 active trials 48 recruiting 21 Phase 3 65 sponsors 10 changes in 30 days
| Early Phase 1 | 10 | |
| Phase 1 | 4 | |
| Phase 1/2 | 3 | |
| Phase 2 | 27 | |
| Phase 2/3 | 2 | |
| Phase 3 | 19 | |
| Phase 4 | 5 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06712407 | Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With… | Calliditas Therapeutics AB | Recruiting | 2026-02-05 |
| NCT07030894 | Nefecon and Ambrisentan in IgA Nephropathy | The First Hospital of Jilin University | Recruiting | 2025-09-15 |
| NCT06676384 | Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can… | Christian Medical College, Vellore, India | Recruiting | 2025-07-14 |
| NCT07604311 | Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy: a Randomized… | Nanfang Hospital, Southern Medical University | Not Yet Recruiting | 2026-05-22 |
| NCT06528015 | Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in… | Gang Xu | Not Yet Recruiting | 2024-07-30 |
| Phase 3 | ||||
| NCT06858319 | Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. | Novartis Pharmaceuticals | Recruiting | 2026-08-17 |
| NCT06963827 | A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy | Takeda | Recruiting | 2026-08-14 |
| NCT07498335 | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in… | Novartis Pharmaceuticals | Recruiting | 2026-08-07 |
| NCT07390123 | Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With… | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | 2026-05-28 |
| NCT07014826 | A Trial of HRS-5965 Capsule in Primary IgA Nephropathy | Chengdu Suncadia Medicine Co., Ltd. | Recruiting | 2025-08-05 |
| NCT06819826 | A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria | Biocity Biopharmaceutics Co., Ltd. | Recruiting | 2025-02-17 |
| NCT05510323 | Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD | Air Force Military Medical University, China | Recruiting | 2024-05-06 |
| NCT07770815 | Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy… | Otsuka Pharmaceutical Development & Commercialization, Inc. | Not Yet Recruiting | 2026-08-18 |
| NCT05797610 | A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants… | Hoffmann-La Roche | Active, Not Recruiting | 2026-08-14 |
| NCT04557462 | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of… | Novartis Pharmaceuticals | Active, Not Recruiting | 2026-07-30 |
| NCT07642050 | A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy | Biohaven Therapeutics Ltd. | Not Yet Recruiting | 2026-06-11 |
| NCT04573478 | Atrasentan in Patients With IgA Nephropathy | Novartis Pharmaceuticals | Active, Not Recruiting | 2026-06-04 |
| NCT03762850 | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA… | Travere Therapeutics, Inc. | Active, Not Recruiting | 2026-04-20 |
| NCT05852938 | A Study of Zigakibart in Adults With IgA Nephropathy | Novartis Pharmaceuticals | Active, Not Recruiting | 2026-04-01 |
| NCT05799287 | A Study of Telitacicept for IgA Nephropathy (TELIGAN) | RemeGen Co., Ltd. | Active, Not Recruiting | 2025-12-16 |
| NCT04716231 | Atacicept in Subjects With IgA Nephropathy | Vera Therapeutics, Inc. | Active, Not Recruiting | 2025-09-30 |
| NCT07098897 | To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in… | The Affiliated Hospital of Xuzhou Medical University | Active, Not Recruiting | 2025-08-01 |
| NCT07052981 | Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric… | Guixia Ding | Not Yet Recruiting | 2025-07-10 |
| NCT06580288 | Effect of Finerenone in IgA Nephropathy | Zhejiang University | Not Yet Recruiting | 2024-08-30 |
| Phase 2/3 | ||||
| NCT03418779 | Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With… | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Active, Not Recruiting | 2024-09-25 |
Novartis Pharmaceuticals (8) · The Children's Hospital of Zhejiang University School of Medicine (5) · Vera Therapeutics, Inc. (3) · Air Force Military Medical University, China (2) · Assistance Publique - Hôpitaux de Paris (2) · Biocity Biopharmaceutics Co., Ltd. (2) · Biohaven Therapeutics Ltd. (2) · Chengdu Suncadia Medicine Co., Ltd. (2) · Guangdong Provincial People's Hospital (2) · Haisco Pharmaceutical Group Co., Ltd. (2)